Atlanta, Georgia, United States
FLUIDDA is a biomedical imaging company specializing in the combination of imaging modalities (CT, MRI, etc), advanced engineering methods like CFD and FEA and Machine Learning. This combination yields sensitive imaging biomarkers to better analyse the efficiency of existing therapies or optimize treatments under development. FLUIDDA is active in a range of different fields such as respiratory, sleep, musculoskeletal and cardiovascular medicine. In addition to providing proprietary technical processes, FLUIDDA also organizes and manages clinical imaging trials in support of the R&D technology. Specialties: imaging biomarkers, computational fluid dynamics (CFD), finite element analysis (FEA), biomedical imaging, research & development biomedical devices, clinical research organization (CRO), Artificial Intelligence, Machine Learning
Medimprove is an international network of cardiopulmonary clinics driven by cutting-edge technology. Our clinics offer advanced diagnostics, including state-of-the-art imaging, targeted therapeutics, and integrated care. We provide a comprehensive, end-to-end solution for patients in need of respiratory care, as well as individuals interested in prevention and longevity.
Every year I give a lecture to students in the Master of Bioscience Enterprise (MBE) program. We discuss innovation in the field of respiratory medicine and we talk about what it takes to start and grow a company in the medical field.
Join the Fight is a non-profit organisation, giving Firefighters and First Responders the medical surveillance they deserve!
The Open Source Imaging Consortium is a cooperative effort between academia, industry and philanthropy to enable rapid advances in the fight against Idiopathic Pulmonary Fibrosis (IPF) and other progressive interstitial lung diseases (ILDs). Radiologists, clinicians and computational scientists from around the world will collaborate on development of digital imaging biomarkers for accurate imaging‑based diagnosis, prognosis and prediction of response to therapy. The partners will work in pre-competitive areas for mutual benefit and, most importantly, the benefit of patients.